Live Breaking News & Updates on Tehran university of medical sciences

Stay informed with the latest breaking news from Tehran university of medical sciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Tehran university of medical sciences and stay connected to the pulse of your community

Octopus-like sucker may mean the end of many jabs

The patches have tiny rubber suction cups and are designed to be stuck on to the inside of the cheek, where they deliver insulin and other drugs for obesity and breast cancer, for instance.

Zurich , Züsz , Switzerland , Tehran , Iran , Swiss , James-birchall , Nevena-paunovi , Tehran-university-of-medical-sciences , Cardiff-university , University-in-zurich , Tehran-university

Feds Gave Money To Iranian State-Run University After Hamas Patched Up Relationship With Tehran

The federal government gave an Iranian state-run university $126,884 in October 2017, shortly after Iran restored its ties with Hamas in August.

Israel , Kazakhstan , Iran , United-states , Syria , Tehran , Islamic-republic-of-iran , American , Iranian , Americans , United-nations

'It was something I had to do' - Wrangler News

'It was something I had to do' - Wrangler News
wranglernews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wranglernews.com Daily Mail and Mail on Sunday newspapers.

Isfahan , Esfahan , Iran , California , United-states , Tehran , Spain , Canada , Tijuana , Baja-california , Mexico , Arizona

Clampdown on Cafes Around Tehran University Sparks Controversy

Tehran, in recent weeks, has witnessed a surge in reports about the complete closure of numerous cafés.

Tehran , Iran , Mihan , Qazvin , Iranian , Hassan-nowruzi , Mobeini-dehkordi , Ali-mobeini-dehkordi , Nika-shakrami , Mohammad-moghimi , Staff-of-the-iranian-armed , Foundation-for-the-preservation-of-works

Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial

Objective To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine.

Design Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.

Setting In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. The last vaccine or placebo injection of the last participant occurred on 15 July 2021 in Isfahan.

Participants 20 000 participants aged 18-75 years were randomly assigned to the intervention or placebo groups with a ratio of 2:1.

Intervention 5 µg vaccine or placebo with the interval of 28 days.

Main outcome measures Vaccine efficacy for a 90 day follow-up period, safety and explanatory immunogenicity assessment, and variant detection during the trial.

Results 20 000 participants were recruited and randomly assigned to receive BIV1-CovIran (n=13 335 (66.7%)) or placebo (n=6665 (33.3%)). Participants' mean age was 38.3 (standard deviation 11.2) years, and 6913 (34.6%) were female. Among vaccinated participants that had covid-19 reported during the follow-up (median 83 days), 758 (5.9%) had symptoms, 144 (1.1%) had severe infection, and seven (0.1%) were critical. Among participants who received placebo during the follow-up, 688 (10.7%) had symptoms, 221 (3.4%) had severe infection, and 19 (0.3%) were critical. Overall efficacy was 50.2% (95% confidence interval 44.7% to 55.0%) against symptomatic covid-19, 70.5% (63.7% to 76.1%) against severe disease, and 83.1% (61.2% to 93.5%) against critical cases. Two deaths were reported in the efficacy population in the placebo group, no deaths were from the intervention group. During follow-up, 41 922 adverse events were reported: 28 782 (68.7%) were adverse reactions, of which 19 363 (67.3%) were in the intervention group. Most adverse reactions were mild or moderate in severity (grade 1 or 2) and self-limiting. No serious adverse events were related to the injections. For variant investigation, of 119 participants positive for the SARS-CoV-2 variant, 106 (89.1%) were positive for the delta variant.

Conclusions A two dose regimen of the BIV1-CovIran vaccine conferred efficacy of 50.2% against symptomatic covid-19, 70.5% against severe disease, and 83.1% against critical disease. Vaccination was well tolerated, with no safety concerns raised.

Trial registration Iranian Registry of Clinical Trials, IRCT20201202049567N3.

Funding Shifa-Pharmed Industrial Group.

De-identified, individual participant data will be made available when the trial is complete, upon requests directed to the corresponding author; after the approval of a proposal, data can be shared through a secure online platform.

Iran , Bushehr , Wuhan , Hubei , China , Mashhad , R30- , Tehran , Shiraz , Fars , Seyyed , Yazd

TyG index simple and cost-effective marker for early detection of people at high risk of HF

Iran: Triglyceride-glucose (TyG) index has demonstrated diagnostic ability in distinguishing heart failure (HF) patients from non-HF individuals, a recent meta-analysis has shown. Regardless of the...

Tehran , Iran , Khalaji , Esfahan , Amir-hossein-behnoush , Cardiovasc-diabetol , Tehran-university-of-medical-sciences , Cardiovascular-diabetology , Tehran-university , Medical-sciences , Eart-failure

Can NT-proBNP level substitute myocardial perfusion scans for CV risk assessment in noncardiac surgeries?

Iran: In patients undergoing noncardiac surgery (NCS), determining the risk of postoperative cardiovascular (CV) complications is fundamental to every preoperative assessment.Results from a recent...

Iran , Tehran , Farnoosh-larti , Tehran-university-of-medical-sciences , Tehran-university , Medical-sciences , Keshavarz-boulevard , Bmc-anesthesiology , Yocardial-perfusion-scan , T-probnp , Reoperative-cardiovascular-risk-assessment

Particulate air pollution a growing risk for premature CVD death and disability worldwide: American Heart Association

Particulate air pollution a growing risk for premature CVD death and disability worldwide: American Heart Association
insurancenewsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insurancenewsnet.com Daily Mail and Mail on Sunday newspapers.

Tehran , Iran , United-states , Dallas , Texas , American , Farshad-farzadfar , American-heart-association , Metabolism-research-institute , Journal-of-the-american-heart-association , Institute-for-health-metrics , Insurance-daily-news-research

Fixed-Dose Combination Therapies Reduce Cardiovascular Risk in CKD

A fixed-dose combination treatment strategy is effective and safe at preventing cardiovascular disease events in patients with CKD.

Iran , United-states , Tehran , American , Reza-malekzadeh , Tehran-university-of-medical-sciences , Tehran-university , Medical-sciences , Clinical-journal , American-society ,

Pollution tied to rise in heart conditions, deaths in new study

Air pollution has contributed to a 30 percent global rise in heart-related disabilities and death since 1990, researchers said.

Iran , United-states , Tehran , American , Charlie-riedel , Farshad-farzadfar , Tehran-university-of-medical-sciences , Journal-of-the-american-heart-association , Institute-for-health-metrics , American-heart-association , American-heart , Global-burden